SCHEMBL4212697

SCHEMBL4212697

Cc1cc(Nc2ccc(Cl)c(Cl)c2)nc(-n2nc(C)cc2C)n1

nearest known ligand 0.80

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KCNN3 Q9UGI6 2/20 0.80
TP53 P04637 4/20 0.76
POLB P06746 4/20 0.76
MAPT P10636 2/20 0.76
LMNA P02545 3/20 0.69
NPSR1 Q6W5P4 2/20 0.65
HIF1A Q16665 1/20 0.65
ALOX15 P16050 2/20 0.61
TSHR P16473 1/20 0.61
MAPK1 P28482 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
HTT P42858 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25193575 0.89 KCNN3 (1.00) KCNN3TP53POLBMAPTLMNA
SCHEMBL4212917 0.86 TP53 (0.80) KCNN3TP53POLBMAPTLMNA
SCHEMBL30421866 0.86 KCNN3 (0.73) KCNN3TP53POLBMAPTLMNA
SCHEMBL25187037 0.86 KCNN3 (0.73) KCNN3TP53POLBMAPTLMNA
SCHEMBL4215477 0.83 TP53 (1.00) KCNN3TP53POLBMAPTLMNA
SCHEMBL4207297 0.82 TP53 (0.71) KCNN3TP53POLBMAPTLMNA
SCHEMBL25199209 0.81 TP53 (0.80) KCNN3TP53POLBMAPTLMNA
SCHEMBL4219187 0.81 TP53 (0.79) KCNN3TP53POLBMAPTLMNA
SCHEMBL15573881 0.80 POLB (1.00) KCNN3TP53POLBMAPTLMNA
SCHEMBL4218566 0.79 LMNA (1.00) KCNN3TP53POLBMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036475-A1 Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use NEUROSEARCH A/S (DK) 2009-02-05 US claimed
EP-1863796-A1 PYRAZOLYL-PYRIMIDINES AS POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-12-12 EP claimed
WO-2006100212-A1 PYRAZOLYL-PYRIMIDINES AS POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-09-28 WO claimed
US-20090036475-A1 Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use NEUROSEARCH A/S (DK) 2009-02-05 US disclosed
EP-1863796-A1 PYRAZOLYL-PYRIMIDINES AS POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-12-12 EP disclosed
WO-2006100212-A1 PYRAZOLYL-PYRIMIDINES AS POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036475-A1 Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use KCND2, KCNJ2, KCNN3 KCNN3 3/4885TP53 1721/4885POLB 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.